Contribute Try STAT+ Today

A highly unusual deal in which Allergan (AGN) is selling patent rights to a Native American tribe is raising troubling questions about the future availability of lower-cost generics — just as prices for prescription medicines are hurting pocketbooks across the country more than ever before.

In a move that took onlookers by surprise, Allergan last Friday announced it will transfer patents for its big-selling Restasis eye drug to the St. Regis Mohawk tribe, which has sovereignty in the U.S. This means the tribe is immune from certain legal claims that generic drug makers typically use to challenge patents held by their brand-name rivals. Such a deal has never been undertaken previously by a drug maker.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • This is what is known as a Fraudulent Conveyance, and it will never stop a lawsuit. All it shows is how desperate Big Pharma is getting as it runs out of ways to gouge the US customer.

  • I just refilled a three-month supply of Restasis for a total cost of $1,255.86. For eye drops! This patent should have expired years ago, and yet here we are allowing Allergan to reap its record profits. It’s positively shameful.

    Is there anything I can do as a consumer besides write to the Senate (which I have done). The cost is prohibitive and unsustainable.

Comments are closed.